Manfred Windisch

Dr. Manfred Windisch founded JSW Lifesciences GmbH, an independent international contract research organization located in Grambach, Austria in the year 1999. JSW specializes on research about neurodegenerative disorders and in his current capacity Dr. Windisch focuses on pharmacological studies of novel compounds for treatment Alzheimer’s, Parkinson’s disease and stroke, from molecular screening up to in vivo model systems, from early screening to phase 3 of clinical studies. In the year 2012 his company was merged with the international CRO QPS, where he continues his work in the function as head of global neuroscience, to further profile the company’s expertise in that field. After graduation from the University of Graz in 1985 he spent several years heading a neurobiology group at the University with research in the field of brain metabolism and animal model development after which he was involved for many years in University and industrial research programs in Europe, North America and Asia. He established a global network of research collaborations and stimulated intensive scientific information exchange. Besides his involvement in basic research on neurotrophic and neuroprotective factors, he spearheaded several international clinical studies in Alzheimer's disease. He is a highly active member of the scientific community and has authored about 100 original research articles in peer-reviewed journals. He is organizing conferences in the field of drug development for treatment of neurodegenerative diseases and is one of the executive organizers of the ADPD conference. As a member of several scientific advisory boards he is helping to coordinate preclinical and clinical research activities in that field on an international level. He is also active in creating improved models of neurodegenerative diseases, which should allow early drug testing with a higher predictive value. In August 2013 he founded a new company “NeuroScios – Neuroscience Optimized Solutions” and took over the position as a CEO there. This company is highly specialized in consulting for complete drug development programs in neurological indications and it provides premier expertise in clinical trials in dementia (AD; MCI and others) as well as cerebro-vascular disorders (stroke). The basis for the quality of his consulting are 35 years of experience in AD-research and about 15 years of intense work with disease models, practically being exposed to all types of treatment approaches for AD.